STOCK TITAN

Cosmos Health Inc. - COSM STOCK NEWS

Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.

Overview of Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ:COSM) is a diversified, vertically integrated global healthcare company specializing in the development, manufacturing, and distribution of nutraceuticals, pharmaceuticals, and over-the-counter (OTC) medicines. Established in 2009 and headquartered in Chicago, Illinois, Cosmos Health operates across multiple business segments, including wholesale drug distribution, proprietary product lines, contract manufacturing, and telehealth services. The company’s vertically integrated model enables it to control every stage of its value chain, from research and development (R&D) to production and global distribution, ensuring high-quality standards and operational efficiency.

Core Business Segments

Nutraceuticals and Proprietary Brands

Cosmos Health is a prominent player in the nutraceuticals market, offering a range of premium products under its proprietary brands, such as Sky Premium Life® and Mediterranation®. These brands are designed to meet the growing demand for health and wellness solutions, with products ranging from dietary supplements to specialized formulations addressing various health needs. The company’s R&D team focuses on creating innovative nutraceuticals, leveraging natural ingredients like Kakadu Plum and advanced formulations such as ZenBlend for relaxation and Skinovate for anti-aging.

Pharmaceuticals and Manufacturing

In the pharmaceutical sector, Cosmos Health provides a comprehensive portfolio of branded generics, OTC medicines, and proprietary complex generics. Its subsidiary, Cana Laboratories S.A., operates under European Good Manufacturing Practices (GMP) and is certified by the European Medicines Agency (EMA). This facility manufactures a wide array of products, including pharmaceuticals, food supplements, cosmetics, and medical devices, ensuring compliance with stringent international quality standards. The company also engages in contract manufacturing for specialty pharmaceutical firms, producing high-demand products such as Baclofen solutions and vitamin B-complex tablets.

Wholesale Distribution

The wholesale segment is a significant revenue driver for Cosmos Health, supplying pharmaceuticals and parapharmaceuticals to retail pharmacies and healthcare providers. With a robust distribution network spanning Europe, Asia, and North America, the company has established itself as a reliable partner for wholesale drug distributors and retail healthcare providers.

Telehealth and Digital Healthcare

Cosmos Health has embraced digital transformation through its telehealth platform, ZipDoctor, Inc. This service offers remote healthcare solutions, catering to the increasing demand for accessible and efficient medical consultations. The integration of telehealth into its business model underscores the company’s commitment to innovation and patient-centric care.

Research and Development (R&D) Initiatives

R&D is a cornerstone of Cosmos Health’s strategy, with a focus on addressing critical health challenges such as obesity, diabetes, cancer, and autoimmune disorders. The company leverages artificial intelligence (AI) through its Cloudscreen platform for drug repurposing, accelerating the development of novel treatments. Recent advancements include patents for anticancer drugs targeting prostate, ovarian, and colorectal cancers, as well as innovative solutions for multiple sclerosis and allergic inflammation.

Global Expansion and Strategic Partnerships

Cosmos Health continues to expand its global footprint through strategic partnerships and distribution agreements. Notable collaborations include exclusive rights to distribute Virax Biolabs’ diagnostic kits in Europe and the Gulf Cooperation Council (GCC) countries. The company’s products are available in leading international retail chains and e-commerce platforms, further solidifying its market presence.

Competitive Positioning

In a competitive healthcare landscape, Cosmos Health differentiates itself through its vertically integrated operations, innovative R&D, and a diverse product portfolio. Its focus on high-margin proprietary brands and strategic geographic expansion positions the company as a growing contender in the global healthcare market.

Conclusion

With a commitment to innovation, quality, and global reach, Cosmos Health Inc. is poised to address some of the most pressing challenges in healthcare. Its diversified business model, coupled with cutting-edge R&D initiatives, ensures a sustainable growth trajectory in the nutraceutical, pharmaceutical, and telehealth sectors.

Rhea-AI Summary
Cosmos Health Inc. has successfully completed the acquisition of Cloudscreen, a cutting-edge AI-powered platform specialized in drug repurposing. Cloudscreen's AI algorithm integrates 1D and 3D data to provide accurate predictions for existing drugs towards new indications, offering higher success rates, heightened safety profiles, and significantly shorter impact times compared to traditional drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. has completed the acquisition of a portfolio of 10 generic drugs, enhancing its pharmaceutical portfolio. The acquisition cost €3.2 million, and the global generic drugs market is projected to reach $613.34 billion by 2030. Cosmos Health aims to capture a substantial share of this market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) expects significant revenue growth from recent acquisitions, projecting a $12.5M increase in FY 2024 group revenue, with a gross profit of at least $3.1M and EBITDA in excess of $1.3M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.07%
Tags
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) announced the acquisition of the license and rights for 'DIABIT-IS X', a generic drug used in the treatment of type-2 diabetes. The drug is set to be launched in Europe following the expiration of the patent for the branded drug 'Januvia'. Cosmos Health aims to capture a significant share of the European market and generate substantial profits from this investment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.33%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) CEO Greg Siokas plans to purchase up to $3 million in common shares through open market transactions, with $1 million already purchased in 2023. Siokas believes the shares are undervalued and intends to increase his stake by approximately 20% of the market capitalization. He has invested over $15 million in the company since inception and sees this as a strategic investment given the innovative R&D projects, AI-drug repurposing, planned spinoff of the R&D department, and international brand growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.49%
Tags
none
-
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) CEO to participate in Invest in Greece Forum, discussing investment opportunities in the healthcare sector. Registration and 1-on-1 meetings available for institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
conferences
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) announced an agreement with Cloudpharm PC to acquire the rights to repurpose a drug for treating various diseases, including CNS cancers and autoimmune diseases. The global brain tumor treatment market is expected to reach $3.1 billion by 2023, with a projected CAGR of 7.2% until 2033. Cosmos Health aims to explore drug repurposing opportunities using advanced technology to deliver medicines faster and more efficiently, targeting major health disorders like cancer, diabetes, and obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) filed a patent application with the European Patent Office for its CCX0722 obesity and weight management product, showcasing significant advancements and promising results in its R&D pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.65%
Tags
none
-
Rhea-AI Summary
Cosmos Health Inc. (COSM) reported Q3 2023 revenues of $12.8M, a 7% increase YoY, with a solid balance sheet, but decreased gross margins and negative Adjusted EBITDA. The company also announced a strategic collaboration, a capital raise, and guidance to surpass $180M in gross annual revenue and $20M in EBITDA by 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.36%
Tags
Rhea-AI Summary
Cosmos Health Inc. announces acquisition of Cloudscreen®, an AI-powered platform for drug repurposing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.71%
Tags

FAQ

What is the current stock price of Cosmos Health (COSM)?

The current stock price of Cosmos Health (COSM) is $0.345 as of April 7, 2025.

What is the market cap of Cosmos Health (COSM)?

The market cap of Cosmos Health (COSM) is approximately 8.7M.

What does Cosmos Health Inc. specialize in?

Cosmos Health Inc. specializes in nutraceuticals, pharmaceuticals, and telehealth, offering proprietary brands and innovative healthcare solutions.

How does Cosmos Health generate revenue?

The company generates revenue through wholesale drug distribution, proprietary product sales, contract manufacturing, and telehealth services.

What are some of Cosmos Health’s proprietary brands?

Key proprietary brands include Sky Premium Life® and Mediterranation®, focusing on high-quality nutraceuticals and wellness products.

What is Cosmos Health’s approach to R&D?

The company leverages AI-driven drug repurposing and innovative research to develop treatments for conditions like cancer, obesity, and autoimmune disorders.

Where does Cosmos Health operate?

Cosmos Health has a global presence, with operations in Europe, Asia, and North America, and distribution centers in Greece and the UK.

What makes Cosmos Health unique in the healthcare industry?

Its vertically integrated model, innovative R&D initiatives, and focus on high-margin proprietary brands set it apart in the competitive healthcare market.

What is the role of AI in Cosmos Health’s operations?

Cosmos Health uses AI through its Cloudscreen platform to accelerate drug repurposing and enhance the development of novel treatments.

What are some recent advancements by Cosmos Health?

Recent advancements include patents for anticancer drugs, a weight management solution, and expansion into telehealth through ZipDoctor.
Cosmos Health Inc.

Nasdaq:COSM

COSM Rankings

COSM Stock Data

8.66M
16.36M
29.66%
6.97%
3.46%
Medical Distribution
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States
THESSALONIKI